The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.
April 22nd 2024
Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.
Therapeutic Advances in Plaque Psoriasis to Address Unmet Needs in Treatment and Improve Patient Outcomes
1.5 Credits / Dermatology
View More
Managed Care Considerations for Management of Molluscum Contagiosum: Examining Emerging Treatments
1.0 Credit / Dermatology
View More
AJMC® Powered by Patients and Managed Care Insights – More Than a Cosmetic Disease: Vitiligo Treatment Approaches and Raising Awareness of the Disease Burden
1.5 Credits / Dermatology
View More
Emerging Treatments Could Add to Targeted Options for Psoriasis, PsA
October 31st 2022Emerging therapies for psoriasis and psoriatic arthritis (PsA) include treatments that target interleukin (IL)-23 and IL-17, which could lead to the approval of new IL-23 and IL-17 inhibitors, as well as expanding the use of currently approved options.
Read More
Level of QOL Impact of Psoriasis Does Not Appear to Be Influenced by Affected Body Region
October 18th 2022Prior to the analysis, researchers hypothesized that having localized psoriasis on more visible and/or more sensitive areas, including the face and genitals, would yield a more significant impact on quality of life.
Read More
Researchers Explore Similarities, Differences in Guidelines for PsA Treatment
October 11th 2022In the last 2 years, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European Alliance of Associations for Rheumatology (EULAR) have updated their recommendations to integrate guidance for new treatment options.
Read More
Does Early Intervention Promote Favorable, Sustained Outcomes in Psoriasis?
October 5th 2022The exploration of whether early intervention has an impact in psoriasis follows data from other immune-mediated diseases in which evidence is mounting for the benefits of intervening early on in disease duration.
Read More
Dr Patrick Burnett on Shared Decision-Making for Moderate to Severe Psoriasis
September 17th 2022Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses clinical recommendations for patients with moderate to severe psoriasis, particularly the need for shared decision-making.
Watch
Dr Patrick Burnett Discusses Efficacy, Safety Profile of Roflumilast Cream in Psoriasis
September 10th 2022Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks on the positive safety and efficacy profile shown in the DERMIS-1 and DERMIS-2 trials exploring use of roflumilast cream in patients with chronic plaque psoriasis, including those with intertriginous disease.
Watch
Researchers Outline Treatment Options for Nail Psoriasis, Other Common Nail Disorders
September 9th 2022Problematic nail conditions range from nail psoriasis (NP) to paronychia, which are commonly seen in clinical practice and result from infectious, inflammatory, neoplastic and traumatic etiologies.
Read More
Dr Patrick Burnett Explains Mechanism of Action for Roflumilast Cream in Psoriasis
August 25th 2022Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA for the treatment of plaque psoriasis in patients aged 12 and older.
Watch
TNF Inhibitors Linked to Higher Risk of Psoriasis in Patients With IBD, RA
August 16th 2022While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).
Read More
Asian Patients With Psoriasis Receive Shortest Visits With Dermatologists
August 3rd 2022Dermatologists spend less time face-to-face with Asian patients with psoriasis compared with patients of other races and ethnicities, despite Asian patients frequently experiencing more severe cases of psoriasis.
Read More
Dr Patrick Burnett Discusses Risk Factors for Adverse Behavioral Health, QOL in Psoriasis
July 23rd 2022Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.
Watch
Dr Patrick Burnett Reviews Patient Survey Findings on Unmet Needs in Psoriasis
July 14th 2022Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to current topical treatments.
Watch
Drug Survival of Psoriasis Biologics Associated With Efficacy, Safety Profile
July 6th 2022Drug survival rates of biologics in patients with psoriasis were shown to be associated with their effectiveness and safety profiles, in which incidence of psoriatic arthritis, nail involvement, and other factors were indicated as effect modifiers.
Read More
Biologic Switching Patterns, Discontinuation in Psoriasis Investigated in New Study
June 22nd 2022An analysis of biologic drug use patterns in patients with psoriasis from Tuscany, Italy, associated etanercept with the highest frequency of switching to other biologics; secukinumab and ustekinumab were linked with the lowest risk.
Read More